Artificial Intelligence
Eli Lilly Expands AI Capabilities with $409M Genetic Leap Partnership
Eli Lilly, AI, Genetic Leap, drug discovery, RNA specialist, pharmaceutical industry
Recursion Pharmaceuticals’ AI-Driven Drug Development Strategy Fails to Impress Investors
Recursion Pharmaceuticals, AI, drug development, investors, biotech, pharmaceuticals
FDA Establishes AI Council to Oversee Ongoing and Future AI Projects
FDA, AI Council, Digital Health Advisory Committee, Artificial Intelligence, Machine Learning, Regulatory Guidance
Qventus Launches AI Operational Assistants to Boost Healthcare Productivity
Qventus, AI Operational Assistants, Healthcare Productivity, Administrative Tasks, Patient Care
Navigating Challenges and Opportunities in the 2024 Life Sciences Industry Outlook
Life Sciences Industry, 2024 Outlook, Biotechnology, Medical Devices, Artificial Intelligence, Drug Pricing, Regulatory Changes, Supply Chain Security, Talent Shortage
Embracing Agility: Critical for the Role of QARA Professional
QARA Professional, Agility, Quality Assurance, Regulatory Affairs, Market Access, Innovative Therapeutic Solutions, AI, Technology, Regulatory Strategy, Leadership, Communication, Diversity, Inclusion.
Revolutionary AI and Brain Implants Restore ALS Patient’s Voice
ALS, brain-computer interface, AI, speech restoration, brain implants, medical breakthrough
Exscientia Merges with Recursion to Form AI-Driven Drug Discovery Leader
Exscientia, Recursion, AI drug discovery, merger, precision chemistry, small molecule synthesis, biotech consolidation
Flagship’s Noubar Afeyan on Uncertainty, AI, and the Future of Biotechnology
, Noubar Afeyan, Flagship Pioneering, Biotechnology, Artificial Intelligence (AI), Uncertainty, Innovation, Future of Biotech, Moderna, Venture Capital,
Healthcare Professionals Seek AI-Powered Personalization and Summarization in Medical Education Content
Healthcare Professionals (HCPs), Artificial Intelligence (AI), Medical Education, Personalization, Summarization